Themis Medicare Announces 55th AGM on September 12, 2025
The AGM and board changes are important corporate events, and the financial performance indicates stability and potential for future growth, meriting a medium impact.
The announcement includes details of the AGM, director appointments, and positive financial performance with revenue growth and strategic initiatives for future growth.
* Themis Medicare Limited will hold its 55th Annual General Meeting (AGM) on Friday, 12th September, 2025 at 10:00 a.m. at the company's Registered Office in Vapi, Gujarat. * The AGM will cover the adoption of audited standalone and consolidated financial statements for the financial year ended 31st March, 2025, the re-appointment of Dr. Adam Demeter as a Director, and the declaration of dividend for FY 2024-25. * Special business includes the ratification of the remuneration of the Cost Auditor (₹3,00,000 per annum plus taxes and expenses) for FY 2025-26, the appointment of Secretarial Auditor M/s. SAV & Associates LLP for 5 years (FY 2025-26 to FY 2029-30), payment of commission to Non-Executive Directors (up to 1% of net profits), and the appointment of Ms. Neha Thakore as an Independent Director. * The company's revenue increased 6.22% YoY to ₹405.51 crore, while EBITDA and PAT stood at ₹49.05 crore and ₹29.83 crore, respectively. * Dr. Sachin D. Patel, Managing Director & CEO, mentioned that the formulations segment delivered remarkable growth, supported by deeper penetration in hospitals and targeted initiatives to drive growth of focused brands. The segment grew over 20% year-on-year in Q3, and continued its strong momentum through Q4. * The company aims to further strengthen its presence in high-potential therapeutic areas, deepen its hospital reach and fast-track high-value product launches and is emphasizing cost rationalization, optimizing field force productivity, enhanced working capital management and selective investments in high-margin brands.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.